# Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

> **NCT07351487** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 37 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab

## Key facts

- **NCT ID:** NCT07351487
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2028-09-25
- **Final completion:** 2030-09-25
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07351487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07351487, "Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07351487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*